Cell-Free Cryopreserved Biological Agents for Cardiac Protection in Autoimmune Myocarditis: A Morphofunctional Animal Model Study
Sažetak
Background/Aim: Autoimmune myocarditis (AIM) is a condition characterised by inflammation of the heart muscle, which can lead to heart failure. The development of effective treatments is crucial for improving cardiac function and recovery. Cell-free cryopreserved biological agents (CF-CBAs), including cell-free placenta extract (CEP), cell-free spleen extract (CES) and mesenchymal stem cell-conditioned medium (CM-MSC), have shown promise in preclinical models for their potential to improve heart function in autoimmune myocarditis. This study aimed to evaluate the efficacy of CEP, CES and CM-MSC in improving cardiac function and structure in a rat model of autoimmune myocarditis.
Methods: CEP and CES were prepared through cryopreservation and water-salt extraction processes from placenta and spleen tissues, respectively. CM-MSC was obtained from umbilical mesenchymal stem cells cultured in serum-free medium. All biological agents were standardised for protein content and administered intramuscularly to rats with induced AIM. The rats were divided into six groups, with treatments administered on days 14, 17, 20, 23 and 26 of the experiment. Electrocardiogram (ECG) and echocardiographic studies were performed to assess heart function on day 28.
Results: The administration of CEP, CES and CM-MSC significantly improved several echocardiographic parameters. Notably, CM-MSC treatment resulted in the most pronounced effects, including a 6.5 % reduction in the end-diastolic diameter of the left ventricle, a 103.4 % increase in ejection fraction, and a 57.3 % improvement in stroke volume. CEP and CES also improved heart function, but to a lesser extent. These treatments reduced left ventricular dilation, improved myocardial contractility and normalised heart wall thickness, with CM-MSC showing superior cardioprotective effects compared to CEP and CES.
Conclusions: The study demonstrates that CEP, CES and CM-MSC have therapeutic potential for improving cardiac function in autoimmune myocarditis. CM-MSC was the most effective in reducing left ventricular dilation and enhancing cardiac output, suggesting its clinical potential for treating autoimmune myocarditis and other cardiovascular diseases.
Reference
Barcena ML, Jeuthe S, Niehues MH, Pozdniakova S, Haritonow N, Kühl AA, et al. Sex-specific differences of the inflammatory state in experimental autoimmune myocarditis. Front Immunol. 2021 May 28;12:686384. doi: 10.3389/fimmu.2021.686384.
Błyszczuk P. Myocarditis in humans and in experimental animal models. Front Cardiovasc Med. 2019 May 16;6:64. doi: 10.3389/fcvm.2019.00064.
Fabre A, Sheppard MN. Sudden adult death syndrome and other non-ischaemic causes of sudden cardiac death. Heart. 2006 Mar;92(3):316-20. doi: 10.1136/hrt.2004.045518.
Mirna M, Paar V, Kraus T, Sotlar K, Wernly B, Pistulli R, et al. Autoimmune myocarditis is not associated with left ventricular systolic dysfunction. Eur J Clin Invest. 2019 Aug;49(8):e13132. doi: 10.1111/eci.13132.
Heidecker B, Ruedi G, Baltensperger N, Gresser E, Kottwitz J, Berg J, et al. Systematic use of cardiac magnetic resonance imaging in MINOCA led to a five-fold increase in the detection rate of myocarditis: a retrospective study. Swiss Med Wkly. 2019 Jul 3;149:w20098. doi: 10.4414/smw.2019.20098.
Fine NM. Rare Causes of autoimmune myocarditis: finding needles in a shifting haystack. JACC Case Rep. 2023 Jan 24;9:101743. doi: 10.1016/j.jaccas.2023.101743.
Zhao J, Li X, Hu J, Chen F, Qiao S, Sun X, et al. Mesenchymal stromal cell-derived exosomes attenuate myocardial ischaemia-reperfusion injury through miR-182-regulated macrophage polarization. Cardiovasc Res. 2019 Jun 1;115(7):1205-16. doi: 10.1093/cvr/cvz040.
Shehadul Islam M, Aryasomayajula A, Selvaganapathy PR. A Review on macroscale and microscale cell lysis methods. Micromachines. 2017; 8(3):83. doi: 10.3390/mi8030083.
Willemars MMA, Nabben M, Verdonschot JAJ, Hoes MF. Evaluation of the interaction of sex hormones and cardiovascular function and health. Curr Heart Fail Rep. 2022 Aug;19(4):200-12. doi: 10.1007/s11897-022-00555-0.
Hladkykh FV. Characterization of the effect of acellular cryopreserved biological agents on antioxidant-prooxidant homeostasis in heart tissues in an autoimmune myocarditis model. Health Educat. 2024;2:23–30. doi: 10.32782/health-2024.2.4.
Shepitko VI. Structural and functional indicators of the cryopreserved liver and the effect of its transplantation on the morphofunctional state of a number of internal organs: dissertation. Doctor of Medicine: special. 14.01.35 – Cryomedicine, Kharkiv, 2004. 326 p. Available at: https://nrat.ukrintei.ua/searchdoc/0504U000610/.
Bespalova IG. Peptide composition and biological action of extracts of cryopreserved pig spleen fragments and piglet skin: thesis. biol. n.: spec. 03.00.19 – Cryobiology, Kharkiv, 2016. 162 p. Available at: https://nrat.ukrintei.ua/searchdoc/0416U004539/.
Caroline Evette Mathen. Patent. A61K35/12. Stem cell conditioned media for clinical and cosmetic applications. Application PCT/IN2018/050078. 2018. Publication of WO2018150440A1. [Internet]. [Cited: 1-Jan-2025]. Available at: https://patents.google.com/patent/WO2018150440A1/.
Golubinskaya PA, Sarycheva MV, Dolzhikov AA, Bondarev VP, Stefanova MS, Soldatov VO, et al. Application of multipotent mesenchymal stem cell secretome in the treatment of adjuvant arthritis and contact-allergic dermatitis in animal models. Pharm Pharmacol. 2020;8(6):416–25. doi: 10.19163/2307-9266-2020-8-6-416-425.
Globa VYu. Use of cryopreserved cell cultures and neurotrophic factors in experimental infravesical obstruction. Thesis in specialty 222 – Medicine, Kharkiv, 2021. 156 p. Available at: https://nrat.ukrintei.ua/searchdoc/0821U100913/.
Pavlenko HP. Free radical, antioxidant, and hemocoagulation processes are normal in experimental heart pathology and their limitation by a peptide bioregulator. Dissertation abstract. Kharkiv. 1993. 20 р.
Hladkykh FV. Freund’s adjuvant is a classic of vaccine adjuvants and the basis of experimental immunology. J V. N. Karazin Kharkiv Nat Univ. Series Med. 2024;32(3(50)):414–39. doi: 10.26565/2313-6693-2024-50-10.
Fontes JA, Barin JG, Talor MV, Stickel N, Schaub J, Rose NR, et al. Complete Freund`s adjuvant induces experimental autoimmune myocarditis by enhancing IL-6 production during initiation of the immune response. Imm Infl Disease. 2017;5(2):163–76. doi: 10.1002/iid3.155.
Root-Bernstein R, Fairweather D. Unresolved issues in theories of autoimmune disease using myocarditis as a framework. J Theor Biol. 2015;375:101–23. doi: 10.1016/j.jtbi.2014.11.022
Chyzh MO, Manchenko AO, Trofimova AV, Belochkina IV. Ultrasound assessment of heart remodelling affected by therapeutic hypothermia and MSC on myocardial infarction model. Ukr J Radiol Oncol. 2020;3(28):222–40. doi: 10.46879/ukroj.3.2020.222-240.
Chyzh MO, Belochkina IV, Globa VYu, Sleta IV, Mikhailova IP, Hladkykh FV. Ultrasound examination of rat hearts after experimental epinephrine-induced damage and the application of heart xenoextract. J V.N. Karazin Kharkiv Nat Univ. Series Med. 2024;32(2(49)):185–97. doi: 10.26565/2313-6693-2024-49-06
Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57(6):450–8. doi: 10.1016/0002-9149(86)90771-x.
Yan F, Robert M, Li Y. Statistical methods and common problems in medical or biomedical science research. Int J Physiol Pathophysiol Pharmacol. 2017;9(5):157–63. PMID: 29209453.
Hladkykh FV, Koshurba MO, Chyzh MO. Characteristics of the antiulcerogenic activity of cryopreserved placenta extract in acute and chronic lesions of the stomach. Mod Med Technol. 2023;56(1):62–8. doi: 10.34287/MMT.1(56).2023.10.
Hladkykh FV, Chyzh MO, Manchenko AO, Belochkina IV, Mikhailova IP. Effect of cryopreserved placenta extract on some biochemical indices of therapeutic efficiency and toxicity of diclofenac sodium in adjuvant-induced experimental arthritis. Pharm Pharmacol. 2021;9(4):278–93. doi: 10.19163/2307-9266-2021-9-4-278-293.
Lotfy A, AboQuella NM, Wang H. Mesenchymal stromal/stem cell (MSC)-derived exosomes in clinical trials. Stem Cell Res Ther. 2023 Apr 7;14(1):66. doi: 10.1186/s13287-023-03287-7.
Ha DH, Kim HK, Lee J, Kwon HH, Park GH, Yang SH, et al. Mesenchymal stem/stromal cell-derived exosomes for immunomodulatory therapeutics and skin regeneration. Cells. 2020 May 7;9(5):1157. doi: 10.3390/cells9051157.
Zhou C, Zhang B, Yang Y, Jiang Q, Li T, Gong J, Tang H, Zhang Q. Stem cell-derived exosomes: emerging therapeutic opportunities for wound healing. Stem Cell Res Ther. 2023 Apr 26;14(1):107. doi: 10.1186/s13287-023-03345-0.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).